Trial Profile
A Phase I And Pharmacogenetic Study Of CPT-11, Oxaliplatin, And Capecitabine In Patients With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 27 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Aug 2007 Status change from recruiting to in progress.
- 17 Aug 2005 New trial record.